Authors: | Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; Langley, E. J.; Kim, P. S.; Covey, A. M.; Caravella, B. A.; Berger, M. F.; Lacouture, M. E.; Hudis, C. A.; Baselga, J.; Chandarlapaty, S.; Dickler, M. N. |
Abstract Title: | Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC) |
Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
Journal Title: | Journal of Clinical Oncology |
Volume: | 32 |
Issue: | 15 Suppl. |
Meeting Dates: | 2014 May 30-Jun 3 |
Meeting Location: | Chicago, IL |
ISSN: | 0732-183X |
Publisher: | American Society of Clinical Oncology |
Date Published: | 2014-05-20 |
Language: | English |
ACCESSION: | WOS:000358613202870 |
PROVIDER: | wos |
DOI: | 10.1200/jco.2014.32.15_suppl.2605 |
Notes: | Meeting Abstract: 2605 -- Source: Wos |